850080-89-6

850080-89-6 structure

Name	Fmoc-Lys(Boc)-OH-13C6,15N2
Synonyms	L-Lysine-13C6-15N2, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- N2-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N6-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-(13C6,15N2)lysine N6-(tert-Butoxycarbonyl)-N2-{[(9H-fluoren-9-yl)methoxy]carbonyl}-L-(13C6,15N2)lysine

Description	Fmoc-L-Lys (Boc)-OH-13C6,15N2 is a 15N-labeled and 13C-labled Triclabendazole.
Related Catalog	Research Areas >> Infection Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[75].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-243. [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-243.

Symbol	GHS09
Signal Word	Warning
Hazard Statements	H410
Precautionary Statements	P273-P501
Personal Protective Equipment	Eyeshields;Gloves
RIDADR	UN 3077 9 / PGIII